# Regeners

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/regeners

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.regenersinc.com
- Total disclosed funding: $1.2M
- Latest round: Seed (Oct 23, 2022)
- Investors on record: 3

## About

Founded in 2021, and based in Daejeon, South Korea, Regeners Inc. is a biotechnology company that conducts research and development of stem cell therapeutics using its proprietary direct reprogramming technology to develop cell regeneration medicine. In October 2022, Regeners raised seed funding from new investor TheVentures. As of January 2023, the company is being led by its CEO, Ha Kang Kim, and its partners include Bluepoint and Y’sLetter. 

The firm employs its proprietary PDR technology (Pluripotency factor-mediated Direct Reprogramming) that analyzes cells in the intermediate stages and induces direct cross-differentiation/development to create a variety of therapeutic cells. The generated cells can be used to reverse the aging in cells and also generate additional nerve cells, cardiomyocytes, liver cells, etc.

## Funding rounds

- Seed, Oct 23, 2022 — The Ventures
- Seed, May 12, 2022, $1.2M — Bluepoint Partners, GTO Investment

## Investors

- Bluepoint Partners (https://capitalatlas.ai/funds/bluepoint-partners) — Seed
- GTO Investment (https://capitalatlas.ai/funds/gto-investment) — Seed
- The Ventures (https://capitalatlas.ai/funds/the-ventures) — Seed